Doctor profile · Federal record
Dr. Sally Campbell, PA-C
Physician Assistant · Physician Assistant · Omaha, NE
- NPI 1134628217
- Accepts Medicare
- 9 yrs in practice
- Licensed in 2 states
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
987400 Nebraska Medical Center
Omaha, NE 681987400
(402) 559-6637 - Mailing address
-
12910 Pierce St, Ste 120
Omaha, NE 681441106
Credentials & registration
- NPI registered
- February 2018 — 8 yrs on file
- Profile last updated
- August 24, 2021
- Year of graduation
- 2017 — 9 yrs since
- Specialty taxonomy
- 363A00000X — NUCC code
- State licenses (2)
- Nebraska #2392 · Iowa #090692
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1134628217. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
3,079
Distinct HCPCS
10
Medicare allowed
$110,628
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 730 | 149 | $5 | |
17003 |
Destruction of precancer skin growth, 2-14 growths | 530 | 74 | $2 | |
11102 |
Biopsy of related skin growth, first growth | 223 | 197 | $69 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 222 | 181 | $71 | |
11103 |
Biopsy of related skin growth, each additional growth | 221 | 104 | $39 | |
17000 |
Destruction of precancer skin growth, 1 growth | 211 | 186 | $34 | |
17110 |
Destruction of skin growth, 1-14 growths | 128 | 122 | $88 | |
17000 |
Destruction of precancer skin growth, 1 growth | 113 | 89 | $37 | |
99203 |
New patient office or other outpatient visit, 30-44 minutes | 97 | 97 | $87 | |
11102 |
Biopsy of related skin growth, first growth | 95 | 80 | $20 |
In context: peer comparison
Among 130 peers in this city , average services per provider: 176. This provider delivers 17× the peer median.Open Payments
Industry payments received
All-time total
$1,306
Transactions
74
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Amgen Inc. | 7 | $240.44 | |
| Lilly USA, LLC | 16 | $210.77 | |
| E.R. Squibb & Sons, L.L.C. | 5 | $165.79 | |
| PFIZER INC. | 24 | $149.29 | |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 6 | $142.90 | |
| Regeneron Healthcare Solutions, Inc. | 1 | $127.23 | |
| ABBVIE INC. | 4 | $67.21 | |
| Novartis Pharmaceuticals Corporation | 2 | $44.41 | |
| GENZYME CORPORATION | 2 | $39.78 | |
| UCB, Inc. | 2 | $33.82 | |
| Janssen Biotech, Inc. | 1 | $22.98 | |
| Galderma Laboratories, L.P. | 1 | $19.71 | |
| Merck Sharp & Dohme LLC | 1 | $14.51 | |
| Arcutis Biotherapeutics, Inc. | 1 | $13.84 | |
| Incyte Corporation | 1 | $13.72 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
594
Patients
399
Total drug cost
$17,828
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Ketoconazole | Generic | 149 | 83 | $2,273 |
| Clobetasol Propionate | Generic | 82 | 47 | $5,963 |
| Triamcinolone Acetonide | Generic | 81 | 61 | $607 |
| Hydrocortisone | Generic | 76 | 67 | $409 |
| Mupirocin | Generic | 59 | 47 | $518 |
| Clindamycin Phosphate | Generic | 41 | 21 | $1,615 |
| Fluorouracil | Generic | 32 | 29 | $3,437 |
| Metronidazole | Generic | 24 | 18 | $1,844 |
| Cephalexin | Generic | 13 | 13 | $70 |
| Doxycycline Hyclate | Generic | 13 | 13 | $309 |
Hospital affiliations
Frequently asked questions
What is Dr. Sally Campbell's medical specialty?
Dr. Sally Campbell practices Physician Assistant in Omaha, NE.
Where does Dr. Sally Campbell practice?
Dr. Sally Campbell practices at 987400 Nebraska Medical Center, Omaha, NE 681987400. Office phone: 4025596637.
What is Dr. Sally Campbell's NPI?
Dr. Sally Campbell's National Provider Identifier (NPI) is 1134628217, issued by NPPES.
Does Dr. Sally Campbell accept Medicare assignment?
Yes. Dr. Sally Campbell accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Sally Campbell commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Biopsy of related skin growth, first growth (HCPCS 11102). Source: CMS Medicare Physician & Other Practitioners file.